Outlook Therapeutics plans to resubmit a biologics license application for ONS-5010, an ophthalmic formulation of bevacizumab, after a trial missed a key target.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Outlook Therapeutics Trial of Eye Disease Treatment Misses Key Endpoint
